{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=49",
    "query": {
      "intervention": "PLACEBO",
      "page": 49
    },
    "page_size": 10
  },
  "pagination": {
    "page": 49,
    "page_size": 10,
    "total_count": 33116,
    "total_pages": 3312,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=50&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=48&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T06:31:01.883Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05170113",
      "title": "Evaluate the Effectiveness and Safety of the Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fatigue"
      ],
      "interventions": [
        {
          "name": "Alpinia galanga formulation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Theacrine formulation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Caffeine formulation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Supplement Formulators, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 79,
      "start_date": "2021-11-02",
      "completion_date": "2022-05-31",
      "has_results": false,
      "last_update_posted_date": "2022-07-28",
      "last_synced_at": "2026-10-30T06:31:01.883Z",
      "location_count": 1,
      "location_summary": "Fort Lauderdale, Florida",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05170113"
    },
    {
      "nct_id": "NCT06408259",
      "title": "Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Fingolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 194,
      "start_date": "2025-04-08",
      "completion_date": "2036-07-13",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-30T06:31:01.883Z",
      "location_count": 12,
      "location_summary": "Loma Linda, California • Sacramento, California • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06408259"
    },
    {
      "nct_id": "NCT03015259",
      "title": "Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Budesonide/Formoterol fumarate dihydrate",
          "type": "DRUG"
        },
        {
          "name": "Symbicort",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kindeva Drug Delivery",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1762,
      "start_date": "2016-12-29",
      "completion_date": "2018-02-08",
      "has_results": true,
      "last_update_posted_date": "2022-08-24",
      "last_synced_at": "2026-10-30T06:31:01.883Z",
      "location_count": 95,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03015259"
    },
    {
      "nct_id": "NCT06755346",
      "title": "The Effects of Cannabis on Male Reproductive Functions",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Male Reproductive Problem"
      ],
      "interventions": [
        {
          "name": "Cannabis plant (THC 20mg)",
          "type": "DRUG"
        },
        {
          "name": "Cannabis (0%/ THC / 0% CBD)",
          "type": "DRUG"
        },
        {
          "name": "Cannabis plant (THC 40mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kanako Hayashi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "64 Years",
        "sex": "MALE",
        "summary": "21 Years to 64 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2025-04-01",
      "completion_date": "2027-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-30T06:31:01.883Z",
      "location_count": 1,
      "location_summary": "Pullman, Washington",
      "locations": [
        {
          "city": "Pullman",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06755346"
    },
    {
      "nct_id": "NCT02437487",
      "title": "SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile"
      ],
      "interventions": [
        {
          "name": "SER-109",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seres Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2015-05",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-10-30T06:31:01.883Z",
      "location_count": 30,
      "location_summary": "Oceanside, California • Sacramento, California • Ventura, California + 26 more",
      "locations": [
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "DeBary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02437487"
    },
    {
      "nct_id": "NCT03004638",
      "title": "Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atherosclerosis",
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "MEDI6012 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "MEDI6012 120 mg",
          "type": "DRUG"
        },
        {
          "name": "MEDI6012 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV Push",
          "type": "DRUG"
        },
        {
          "name": "MEDI6012 IV Push",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "60 Years to 80 Years"
      },
      "enrollment_count": 32,
      "start_date": "2017-01-23",
      "completion_date": "2017-11-02",
      "has_results": true,
      "last_update_posted_date": "2018-12-19",
      "last_synced_at": "2026-10-30T06:31:01.883Z",
      "location_count": 4,
      "location_summary": "Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 1 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03004638"
    },
    {
      "nct_id": "NCT03560258",
      "title": "HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "p24CE1/2 pDNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Full-length p55^gag pDNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 45,
      "start_date": "2019-03-26",
      "completion_date": "2021-02-10",
      "has_results": true,
      "last_update_posted_date": "2022-04-26",
      "last_synced_at": "2026-10-30T06:31:01.883Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03560258"
    },
    {
      "nct_id": "NCT03188185",
      "title": "A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "ALKS 5461",
          "type": "DRUG"
        },
        {
          "name": "ALKS 5461 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkermes, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 278,
      "start_date": "2017-06-12",
      "completion_date": "2020-03-05",
      "has_results": true,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-10-30T06:31:01.883Z",
      "location_count": 30,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 27 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Pico Rivera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03188185"
    },
    {
      "nct_id": "NCT02412735",
      "title": "Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Degenerative Disc Disease"
      ],
      "interventions": [
        {
          "name": "Rexlemestrocel-L",
          "type": "DRUG"
        },
        {
          "name": "Rexlemestrocel-L + HA Mixture",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mesoblast, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 404,
      "start_date": "2015-03-06",
      "completion_date": "2021-06-15",
      "has_results": true,
      "last_update_posted_date": "2022-10-19",
      "last_synced_at": "2026-10-30T06:31:01.883Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "El Cajon",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02412735"
    },
    {
      "nct_id": "NCT03182725",
      "title": "Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postural Orthostatic Tachycardia Syndrome"
      ],
      "interventions": [
        {
          "name": "Ivabradine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 37,
      "start_date": "2018-02-06",
      "completion_date": "2020-05-08",
      "has_results": true,
      "last_update_posted_date": "2021-06-29",
      "last_synced_at": "2026-10-30T06:31:01.883Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03182725"
    }
  ]
}